News
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
14d
Axios on MSNVinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
Wellbeing Whisper on MSN1d
Why Most Americans Won't Need Covid Boosters Anymore and What It Means for YouWe want to know more about what these products are doing,” said Dr. Vinay Prasad during a recent FDA livestreamed ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
FDA Commissioner Marty Makary named Vinay Prasad, a hematologist oncologist and critic of the Covid-19 vaccine for children, as the next director of the Center for Biologics and Research.
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene therapies, and blood supply.
15d
Scripps News on MSNDrug industry critic Vinay Prasad will lead FDA's vaccine oversightVinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and gene therapy regulation.
The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...
15don MSN
Controversial oncoologist-haematologist Vinay Prasad will be the FDA's top vaccine regulator. Apart from his extensive research and contribution in the field of oncology, he is known for his scathing ...
WASHINGTON — Vinay Prasad, an academic and fierce ... including the Center for Biologics Evaluation and Research, the unit he will now lead. After reports of his appointment, the S&P Biotech ...
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results